Clinical Trials

In this study, we seek to perform a survey of patients who had surgery performed at Mayo Clinic for Ebstein's anomaly, asking for growth charts when available, and giving patients a limited developmental screening questionnaire and quality of life questionnaire.  We seek to try to determine the specific age at which repair of Ebstein's anomaly may result in improved long-term outcomes beyond the operating room.

The objective of this study is to evaluate the safety and feasibility of autologous mononuclear cells (MNC) collected from bone marrow (BM) delivered into the myocardium of the right ventricle of subjects with Ebstein anomaly undergoing surgical Ebstein repair. Additionally, the potential cardiovascular benefits will also be evaluated. This add-on procedure is anticipated to pose little risk to the subject and has the potential to foster a new strategy that leverages the regenerative capacity of individuals with congenital heart disease during the surgically mandated Ebstein repair.

The purporse of this study is to determine if biomarker assay obtained at baseline can predict future risk of cardiovascular adverse events, and to  determine if temporal changes in biomarker levels can provide a better risk prediction compared to biomarker assay obtained at baseline.